Congcong Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Congcong Sun has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Chengyuan Song
Department of Neurology, The Qilu Hospital, Shandong University, Jinan, China
1 shared publication Danyu Li
Integrated Devices and Intelligent Diagnosis (ID2) Laboratory, CUHKSZ‐Boyalife Joint Laboratory of Regenerative Medicine Engineering, Biomedical Engineering Programme, School of Medicine The Chinese University of Hong Kong Shenzhen China
1 shared publicationGuoyong Jia
Department of Neurology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan
1 shared publication- Guoyong Jia
Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Neurol, Jinan, Peoples R China
1 shared publication - Guozhen Liu
The Chinese University of Hong Kong
1 shared publication Hongna Yang
Department of Critical-care Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan
1 shared publication
Latest Publications
- Open Access
- 19 June 2024
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 13 (6) , e12467
Isolation and quantification of L1CAM‐positive extracellular vesicles on a chip as a potential biomarker for Parkinson's Disease
Extracellular vesicles (EVs) carry disease‐specific molecular profiles, demonstrating massive potential in biomarker discovery. In this study, we developed an integrated biochip platform, termed EVID‐biochip (EVs identification and detection biochip), which integrates in situ electrochemical protein detection with on‐chip antifouling‐immunomagnetic beads modified with CD81 antibodies and zwitterion molecules, enabling efficient isolation and detection of neuronal EVs. The capability of the EVID‐biochip to isolate common EVs and detect neuronal EVs associated with Parkinson's disease in human serum is successfully demonstrated, using the transmembrane protein L1‐cell adhesion molecule (L1CAM) as a target biomarker. The EVID‐biochip exhibited high efficiency and specificity for the detection of L1CAM with a sensitivity of 1 pg/mL. Based on the validation of 76 human serum samples, for the first time, this study discovered that the level of L1CAM/neuronal EV particles in serum could serve as a reliable indicator to distinguish Parkinson's disease from control groups with AUC = 0.973. EVID‐biochip represents a reliable and rapid liquid biopsy platform for the analysis of complex biofluids offering EVs isolation and detection in a single chip, requiring a small sample volume (300 µL) and an assay time of 1.5 h. This approach has the potential to advance the diagnosis and biomarker discovery of various neurological disorders and other diseases.
- 19 June 2024
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 13 (6) , e12467
Open AccessIsolation and quantification of L1CAM‐positive extracellular vesicles on a chip as a potential biomarker for Parkinson's Disease
Extracellular vesicles (EVs) carry disease‐specific molecular profiles, demonstrating massive potential in biomarker discovery. In this study, we developed an integrated biochip platform, termed EVID‐biochip (EVs identification and detection biochip), which integrates in situ electrochemical protein detection with on‐chip antifouling‐immunomagnetic beads modified with CD81 antibodies and zwitterion molecules, enabling efficient isolation and detection of neuronal EVs. The capability of the EVID‐biochip to isolate common EVs and detect neuronal EVs associated with Parkinson's disease in human serum is successfully demonstrated, using the transmembrane protein L1‐cell adhesion molecule (L1CAM) as a target biomarker. The EVID‐biochip exhibited high efficiency and specificity for the detection of L1CAM with a sensitivity of 1 pg/mL. Based on the validation of 76 human serum samples, for the first time, this study discovered that the level of L1CAM/neuronal EV particles in serum could serve as a reliable indicator to distinguish Parkinson's disease from control groups with AUC = 0.973. EVID‐biochip represents a reliable and rapid liquid biopsy platform for the analysis of complex biofluids offering EVs isolation and detection in a single chip, requiring a small sample volume (300 µL) and an assay time of 1.5 h. This approach has the potential to advance the diagnosis and biomarker discovery of various neurological disorders and other diseases.
- RetractionOpen Access
- 19 June 2020
- Published by PAGEPress Publications in European Journal of Histochemistry
- Vol. 64 (s2)
Retraction: Neural stem cell conditioned medium alleviates Aβ25-35 damage to SH-SY5Y cells through the PCMT1/MST1 pathway
On behalf of the coauthors and with much regret, I must retract our publication entitled “Neural stem cell conditioned medium alleviates Aβ25-35 damage to SH-SY5Y cells through the PCMT1/MST1 pathway” published on European Journal of Histochemistry 2020;64(s2):3135 for the following reasons: In Figure 1A, the data of 20 μM Aβ25-35 for different time were confused with the data of 30 μM Aβ25-35 for different time. In Figure 2, the differential expression of PCMT1 is poor in repeatability. The authors need to revise the experimental design and steps to verify it again, re-do the experiment and conduct a more in-depth study. Dr. Congcong Sun Department of Neurology Qilu Hospital Cheeloo College of Medicine Shandong University China
- 19 June 2020
- Published by PAGEPress Publications in European Journal of Histochemistry
- Vol. 64 (s2)
RetractionOpen AccessRetraction: Neural stem cell conditioned medium alleviates Aβ25-35 damage to SH-SY5Y cells through the PCMT1/MST1 pathway
On behalf of the coauthors and with much regret, I must retract our publication entitled “Neural stem cell conditioned medium alleviates Aβ25-35 damage to SH-SY5Y cells through the PCMT1/MST1 pathway” published on European Journal of Histochemistry 2020;64(s2):3135 for the following reasons: In Figure 1A, the data of 20 μM Aβ25-35 for different time were confused with the data of 30 μM Aβ25-35 for different time. In Figure 2, the differential expression of PCMT1 is poor in repeatability. The authors need to revise the experimental design and steps to verify it again, re-do the experiment and conduct a more in-depth study. Dr. Congcong Sun Department of Neurology Qilu Hospital Cheeloo College of Medicine Shandong University China
- RetractedOpen Access
- 19 June 2020
- Published by PAGEPress Publications in European Journal of Histochemistry
- Vol. 64 (s2)
Neural stem cell conditioned medium alleviates Aβ25-35 damage to SH-SY5Y cells through the PCMT1/MST1 pathway
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease. Accumulating evidence suggests that protein isoaspartate methyltransferase 1 (PCMT1) is highly expressed in brain tissue (substantia nigra, blue plaque, paraventricular nucleus). In this study, we investigated the effect of neural stem cell conditioned medium alleviates Aβ25-35 damage to SH-SY5Y cells by PCMT1/MST1 pathway. Results demonstrated that Aβ25-35 significantly decreased the cell viability in time and dose dependent manner. However, Neural stem cell-complete medium (NSC-CPM) or NSC-CDM had inhibitory effect on toxicity when fibrillation of Aβ25-35 occurred in their presence and NSC-CDM had a better inhibitor result. An increase of the PCMT1 expression levels was found in Aβ25-35 + NSC-CDM group. sh-PCMT1 significantly reduced the PCMT1, the cell viability and inhibited the protective effect; induced apoptosis and increased the expression of p-MST1. Overexpression of PCMT1 group reversed the effect of Aβ25-35 inhibited the cell viability and Aβ25-35 induced the apoptosis. In conclusion, NSC-CDM corrects the damage of Aβ25-35 to cells by increasing PCMT1, reducing MST phosphorylation.
- 19 June 2020
- Published by PAGEPress Publications in European Journal of Histochemistry
- Vol. 64 (s2)
RetractedOpen AccessNeural stem cell conditioned medium alleviates Aβ25-35 damage to SH-SY5Y cells through the PCMT1/MST1 pathway
Alzheimer’s disease (AD) is a progressive, neurodegenerative disease. Accumulating evidence suggests that protein isoaspartate methyltransferase 1 (PCMT1) is highly expressed in brain tissue (substantia nigra, blue plaque, paraventricular nucleus). In this study, we investigated the effect of neural stem cell conditioned medium alleviates Aβ25-35 damage to SH-SY5Y cells by PCMT1/MST1 pathway. Results demonstrated that Aβ25-35 significantly decreased the cell viability in time and dose dependent manner. However, Neural stem cell-complete medium (NSC-CPM) or NSC-CDM had inhibitory effect on toxicity when fibrillation of Aβ25-35 occurred in their presence and NSC-CDM had a better inhibitor result. An increase of the PCMT1 expression levels was found in Aβ25-35 + NSC-CDM group. sh-PCMT1 significantly reduced the PCMT1, the cell viability and inhibited the protective effect; induced apoptosis and increased the expression of p-MST1. Overexpression of PCMT1 group reversed the effect of Aβ25-35 inhibited the cell viability and Aβ25-35 induced the apoptosis. In conclusion, NSC-CDM corrects the damage of Aβ25-35 to cells by increasing PCMT1, reducing MST phosphorylation.
- Open Access
- 5 March 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-7
Minocycline Protects against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinson’s Disease Rat Model
The aim of this study was to investigate the effect of minocycline in rats with rotenone-induced Parkinson’s disease (PD). The open field test was performed to determine the motor ability of the rats. Double immunofluorescence staining was used to detect the expression of tyrosine hydroxylase (TH) and Nurr1 in the substantia nigra (SN) of rats. The relative protein levels of TH, Nurr1, and the total- and phosphorylated-cAMP-response element binding protein (CREB) were determined by western blot analysis. The production of reactive oxygen species (ROS) and nitric oxide (NO) was detected by commercial kits. After exposure to rotenone for 28 days, rats exhibited decreased ambulation and rearing frequency and prolonged immobility time with loss of TH positive neurons in the SN. The phosphorylation levels of CREB and Nurr1 expression decreased significantly accompanied with the release of ROS and NO. Minocycline alleviated the motor deficits of rats lesioned by rotenone and elevated the expression of TH, as well as suppressing the release of ROS and NO in the SN. That was in line with the elevated phosphorylation levels of CREB and Nurr1 expression. In conclusion, our present study showed minocycline protected against neurotoxicity in a rotenone-induced rat model of PD, which was correlated with upregulation of Nurr1.
- 5 March 2019
- Published by Wiley in BioMed Research International
- Vol. 2019, 1-7
Open AccessMinocycline Protects against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinson’s Disease Rat Model
The aim of this study was to investigate the effect of minocycline in rats with rotenone-induced Parkinson’s disease (PD). The open field test was performed to determine the motor ability of the rats. Double immunofluorescence staining was used to detect the expression of tyrosine hydroxylase (TH) and Nurr1 in the substantia nigra (SN) of rats. The relative protein levels of TH, Nurr1, and the total- and phosphorylated-cAMP-response element binding protein (CREB) were determined by western blot analysis. The production of reactive oxygen species (ROS) and nitric oxide (NO) was detected by commercial kits. After exposure to rotenone for 28 days, rats exhibited decreased ambulation and rearing frequency and prolonged immobility time with loss of TH positive neurons in the SN. The phosphorylation levels of CREB and Nurr1 expression decreased significantly accompanied with the release of ROS and NO. Minocycline alleviated the motor deficits of rats lesioned by rotenone and elevated the expression of TH, as well as suppressing the release of ROS and NO in the SN. That was in line with the elevated phosphorylation levels of CREB and Nurr1 expression. In conclusion, our present study showed minocycline protected against neurotoxicity in a rotenone-induced rat model of PD, which was correlated with upregulation of Nurr1.